Patents by Inventor Phillip Dan Cook

Phillip Dan Cook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5922872
    Abstract: Compositions comprising meta-benzylic compounds are prepared. The compositions are useful as antibacterial and as other pharmaceutical agents and as intermediates for preparation of other pharmaceutical agents. In addition, compositions of the present invention are useful as research reagents.
    Type: Grant
    Filed: August 1, 1996
    Date of Patent: July 13, 1999
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Andrew M. Kawasaki
  • Patent number: 5914396
    Abstract: 2'-O-Modified nucleosides, nucleotides, and oligonucleotides. These 2'-O-modified oligonucleotides are resistant to nuclease digestion and can effectively hybridize to a complementary polynucleotide.
    Type: Grant
    Filed: February 22, 1995
    Date of Patent: June 22, 1999
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Charles John Guinosso
  • Patent number: 5886177
    Abstract: Novel ethylene glycol compounds bearing various functional groups are used to prepare oligomeric structures. The ethylene glycol monomers can be joined via standard phosphate linkages including phosphorothioate, phosphodiester, and phosphoramidate linkages. Useful functional groups include nucleobases as well as polar groups, hydrophobic groups, ionic groups, aromatic groups and/or groups that participate in hydrogen-bonding.
    Type: Grant
    Filed: August 8, 1996
    Date of Patent: March 23, 1999
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Oscar L. Acevedo, Peter W. Davis, David J. Ecker, Normand Hebert
  • Patent number: 5872232
    Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the 2'-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of diseases caused by various viruses and other causative agents is provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 16, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Phillip Dan Cook, Andrew Mamoru Kawasaki
  • Patent number: 5864010
    Abstract: New sub-monomer synthetic methods for the preparation of peptide nucleic acid oligomeric structures are disclosed that provide for the synthesis of both predefined sequence peptide nucleic acid oligomers as well as random sequence peptide nucleic acid oligomers. Further these methods also provide for the incorporation of peptide nucleic acid units or strings of such units with amino acids or strings of amino acids in chimeric peptide nucleic acid-amino acid compounds. Further disclosed are method of making random libraries of peptide nucleic acids using the fully preformed monomers.
    Type: Grant
    Filed: January 17, 1996
    Date of Patent: January 26, 1999
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, John Kiely, Kelly Sprankle
  • Patent number: 5861493
    Abstract: Improved processes for the synthesis of 2'-O-substituted pyrimidine nucleosides are provided. The processes feature alkylation of a 2,2'-anhydropyrimidine nucleoside or a 2S,2'-anhydropyrimidine nucleoside with a weak nucleophile in the presence of a Lewis acid.
    Type: Grant
    Filed: July 9, 1997
    Date of Patent: January 19, 1999
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Robert H. Springer, Kelly G. Sprankle, Bruce S. Ross
  • Patent number: 5859221
    Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the 2'-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of diseases caused by various viruses and other causative agents is provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 12, 1999
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Andrew Mamoru Kawasaki
  • Patent number: 5856466
    Abstract: Processes for preparing 2'-O-alkylated guanosine, uridine, cytidine, and 2,6-diaminopurine 3'-O-phosphoramidites include the steps of alkylating nucleoside precursors, adding suitable blocking groups and phosphitylating. For the guanosine 2'-O-alkylated 3'-O-phosphoramidites, alkylation is effected on 2,6-diamino-9-(.beta.-D-ribofuranosyl)purine followed by deamination. For uridine 2'-O-alkylated 3'-O-phosphoramidites, alkylation is effect on a dialkyl stannylene derivative of uridine. For cytidine 2'-O-alkylated 3'-O-phosphoramidites, alkylation is effected directly on cytidine. Alkylation is effected directly upon 2,6-diaminopurine.
    Type: Grant
    Filed: July 7, 1997
    Date of Patent: January 5, 1999
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Daniel Peter Claude McGee, Charles John Guinosso
  • Patent number: 5856455
    Abstract: Oligonucleotides and other macromolecules are provided that have increased nuclease resistance, substituent groups for increasing binding affinity to complementary strand, and subsequences of 2'-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H enzyme. Such oligonucleotides and macromolecules are useful for diagnostics and other research purposes, for modulating protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to antisense therapeutics.
    Type: Grant
    Filed: April 21, 1997
    Date of Patent: January 5, 1999
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Phillip Dan Cook
  • Patent number: 5852188
    Abstract: Sequence-specific oligonucleotides are provided having substantially pure chiral Sp phosphorothioate, chiral Rp phosphorothioate, chiral Sp alkylphosphonate, chiral Rp alkylphosphonate, chiral Sp phosphoamidate, chiral Rp phosphoamidate, chiral Sp phosphotriester, and chiral Rp phosphotriester linkages. The novel oligonucleotides are prepared via a stereospecific SN.sub.2 nucleophilic attack of a phosphodiester, phosphorothioate, phosphoramidate, phosphotriester or alkylphosphonate anion on the 3' position of a xylonucleotide. The reaction proceeds via inversion at the 3' position of the xylo reactant species, resulting in the incorporation of phosphodiester, phosphorothioate, phosphoramidate, phosphotriester or alkylphosphonate linked ribofuranosyl sugar moieties into the oligonucleotide.
    Type: Grant
    Filed: April 19, 1996
    Date of Patent: December 22, 1998
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Phillip Dan Cook
  • Patent number: 5852182
    Abstract: Nucleosides and linked nucleosides functionalized to include alkylthiol chemical functionality at ribofuranosyl positions, nucleosidic base positions, or on internucleoside linkages. In certain embodiments, the compounds of the invention further include steroids, reporter molecules, reporter enzymes, lipophilic molecules, peptides or proteins attached to the nucleosides through the alkylthio group.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 22, 1998
    Assignee: ISIS Pharmaceuticals Inc.
    Inventors: Phillip Dan Cook, Muthiah Manoharan
  • Patent number: 5847106
    Abstract: Synthetic processes are provided wherein substituted silylalkyl phosphoramidites serve as coupling reagents for preparing phosphate, phosphorothioate, and other phosphorous-containing covalent linkages. Also provided are synthetic intermediates useful in such processes. h processes.
    Type: Grant
    Filed: January 27, 1997
    Date of Patent: December 8, 1998
    Assignee: ISIS Pharmaceuticals Inc.
    Inventors: Vasulinga Ravikumar, Dennis Mulvey, Douglas L. Cole, Phillip Dan Cook
  • Patent number: 5831014
    Abstract: New sub-monomer synthetic methods for the preparation of peptide nucleic acid oligomeric structures are disclosed that provide for the synthesis of both predefined sequence peptide nucleic acid oligomers as well as random sequence peptide nucleic acid oligomers. Further these methods also provide for the incorporation of peptide nucleic acid units or strings of such units with amino acids or strings of amino acids in chimeric peptide nucleic acid-amino acid compounds. Further disclosed are methods of making random libraries of peptide nucleic acids using the fully preformed monomers.
    Type: Grant
    Filed: August 13, 1996
    Date of Patent: November 3, 1998
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, John Kiely, Kelly Sprankle
  • Patent number: 5817489
    Abstract: Compositions comprising novel di-nitrogen heterocycle compounds containing at least one N-meta-substituted alkaryl group are prepared. The compounds of the present invention are useful as antibacterial and as other pharmaceutical agents and as intermediates for preparation of other pharmaceutical agents. In addition, compounds of the present invention are useful as research reagents.
    Type: Grant
    Filed: August 1, 1996
    Date of Patent: October 6, 1998
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Pei Pei Kung, Andrew M. Kawasaki
  • Patent number: 5811534
    Abstract: This invention is directed to novel purine-based compounds for inclusion into oligonucleotides. The compounds of the invention, when incorporated into oligonucleotides are especially useful as "antisense" agents--agents that are capable of specific hybridization with a nucleotide sequence of an RNA. The compounds of the invention may also be used for cross-linking oligonucleotides. Oligonucleotides are used for a variety of therapeutic and diagnostic purposes, such as treating diseases, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins, and cleaving RNA in site specific fashions. The compounds of the invention include novel heterocyclic bases, nucleosides, and nucleotides. When incorporated into oligonucleotides, the compounds of the invention can be useful for modulating the activity of RNA.
    Type: Grant
    Filed: October 9, 1997
    Date of Patent: September 22, 1998
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Muthiah Manoharan, Kanda S. Ramasamy
  • Patent number: 5808023
    Abstract: Novel compounds that mimic and/or modulate the activity of wild-type nucleic acids are provided. The novel compounds have modified internucleoside linkages which preferably replace naturally-occurring phosphodiester-5'-methylene linkages with four atom linking groups. Preferred linkages have structures such as, for example, CH.sub.2 --R.sub.A --NR.sub.1 --CH.sub.2, CH.sub.2 --NR.sub.1 --R.sub.A --CH.sub.2, R.sub.A --NR.sub.1 --CH.sub.2 --CH.sub.2, CH.sub.2 --CH.sub.2 --NR.sub.1 --R.sub.A, CH.sub.2 --CH.sub.2 --R.sub.A --NR.sub.1, or NR.sub.1 --R.sub.A --CH.sub.2 --CH.sub.2 where R.sub.A is O or NR.sub.2. These linkages are prepared from appropriately functionalized nucleosides and oligonucleotides.
    Type: Grant
    Filed: November 7, 1994
    Date of Patent: September 15, 1998
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Yogesh S. Sanghvi, Phillip Dan Cook
  • Patent number: 5808027
    Abstract: This invention presents novel purine-based compounds for inclusion into oligonucleotides. The compounds of the invention, when incorporated into oligonucleotides are especially useful as "antisense" agents--agents that are capable of specific hybridization with a nucleotide sequence of an RNA. Oligonucleotides are used for a variety of therapeutic and diagnostic purposes, such as treating diseases, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins, and cleaving RNA in site specific fashions. The compounds of the invention include novel heterocyclic bases, nucleosides, and nucleotides. When incorporated into oligonucleotides, the compounds of the invention can be useful for modulating the activity of RNA.
    Type: Grant
    Filed: December 10, 1996
    Date of Patent: September 15, 1998
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Kanda S. Ramasamy, Muthiah Manoharan
  • Patent number: 5798360
    Abstract: Compositions are provided comprising novel di-nitrogen heterocycle compounds containing N-(aminoalkyl) and/or N-(amidoalkyl) groups. An additional situs of functionality is also provided. The compounds and compositions of the invention are useful as antibacterial and other pharmaceutical agents and as intermediates for preparation of other pharmaceutical agents. In addition, compounds of the present invention are useful as research reagents including employment as species for effecting combinatorial synthesis.
    Type: Grant
    Filed: August 1, 1996
    Date of Patent: August 25, 1998
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Andrew M. Kawasaki, Pei Pei Kung
  • Patent number: 5792844
    Abstract: Novel compounds that mimic and/or modulate the activity of wild-type nucleic acids. In general, the compounds contain a selected nucleoside sequence wherein the nucleosides are covalently bound through linking groups that contain adjacent nitrogen atoms.
    Type: Grant
    Filed: October 3, 1994
    Date of Patent: August 11, 1998
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Yogesh S. Sanghvi, Phillip Dan Cook
  • Patent number: 5780241
    Abstract: Compositions comprising novel chemical libraries are prepared. The compositions of the present invention are useful as antibacterial and other pharmaceutical agents and as intermediates for preparation other pharmaceutical agents. In addition, compounds of the present invention are useful as research reagents.
    Type: Grant
    Filed: November 5, 1996
    Date of Patent: July 14, 1998
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Phillip Dan Cook